McKesson Corporation (MCK)
NYSE: MCK
· Real-Time Price · USD
673.84
10.67 (1.61%)
At close: Aug 14, 2025, 3:59 PM
680.00
0.91%
After-hours: Aug 14, 2025, 07:38 PM EDT
McKesson Revenue Breakdown
| Period Ending | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2015 | Mar 31, 2014 | Mar 31, 2013 | Mar 31, 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| International Segment Revenue | 14.72B | 14.13B | 20.6B | 36.34B | 35.97B | 8.3B | 7.62B | 5.91B | 5.65B | 3.61B | 3.15B |
| International Segment Revenue Growth | +4.18% | -31.40% | -43.33% | +1.06% | +333.05% | +9.02% | +28.97% | +4.59% | +56.41% | +14.82% | n/a |
| Medical-Surgical Solutions Segment Revenue | 11.39B | 11.31B | 11.11B | 11.61B | 10.1B | 183.34B | 167.76B | n/a | n/a | n/a | n/a |
| Medical-Surgical Solutions Segment Revenue Growth | +0.65% | +1.83% | -4.29% | +14.94% | -94.49% | +9.29% | n/a | n/a | n/a | n/a | n/a |
| Prescription Technology Solutions Revenue | 5.22B | 4.77B | 4.39B | 3.86B | 2.89B | n/a | n/a | n/a | n/a | n/a | n/a |
| Prescription Technology Solutions Revenue Growth | +9.37% | +8.71% | +13.54% | +33.70% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| U.S. Pharmaceutical Segment Revenue | 327.72B | 278.74B | 240.62B | 212.15B | 189.27B | n/a | n/a | n/a | n/a | n/a | n/a |
| U.S. Pharmaceutical Segment Revenue Growth | +17.57% | +15.84% | +13.42% | +12.09% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 | Mar 31, 2016 | Mar 31, 2015 | Mar 31, 2014 | Mar 31, 2013 | Mar 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|
| International Segment Revenue | 38.34B | 38.02B | 38.41B | 34.1B | 32.63B | 142.81B | 122.43B | 112.28B | 102.09B |
| International Segment Revenue Growth | +0.84% | -1.02% | +12.63% | +4.52% | -77.15% | +16.65% | +9.03% | +9.99% | n/a |
| United States Revenue | 192.71B | 176.3B | 169.94B | 164.43B | 158.25B | n/a | n/a | n/a | 9.99B |
| United States Revenue Growth | +9.31% | +3.74% | +3.35% | +3.90% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | -2.2B | 1.88B | 1.93B | 2.4B | 1.9B | 2.09B | 2.41B | 2B | 1.77B | 1.87B | 1.82B | 1.86B | 1.87B | 2.43B | 2.99B | 2.54B | 2.09B | 2.05B | 2.11B | 2.05B | 1.91B | 1.9B | 2.42B | 2.08B | 2.02B | 2.02B | 2.03B | 1.91B | 2B | 2.11B | 1.79B | 1.88B | 1.83B | 1.98B | 1.8B | 1.75B | 1.94B | 1.91B | 1.95B | 1.89B | 1.92B | 2.07B |
| Selling, General, and Administrative Revenue Growth | -216.56% | -2.53% | -19.49% | +26.70% | -9.37% | -13.20% | +20.45% | +12.68% | -4.88% | +2.75% | -2.47% | -0.53% | -23.06% | -18.55% | +17.51% | +21.39% | +2.05% | -2.89% | +2.92% | +7.37% | +0.79% | -21.68% | +16.55% | +2.97% | -0.10% | -0.69% | +6.38% | -4.64% | -4.89% | +17.70% | -4.89% | +2.67% | -7.23% | +9.65% | +3.32% | -9.82% | +1.36% | -2.20% | +3.28% | -1.41% | -7.26% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 392M | n/a | n/a | n/a | 392M |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | n/a | -100.00% | n/a |